Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sanaz,Ghafouri

第一单位： UCLA Medical Center, Hematology Oncology, Los Angeles CA. Electronic address: snghafouri@mednet.ucla.edu.

作者： Sanaz,Ghafouri ^[1] ; Kathleen,Fenerty ^[2] ; Gary,Schiller ^[3] ; Sven,de Vos ^[3] ; Herbert,Eradat ^[3] ; John,Timmerman ^[3] ; Sarah,Larson ^[3] ; Monica,Mead ^[3]

作者单位： UCLA Medical Center, Hematology Oncology, Los Angeles CA. Electronic address: snghafouri@mednet.ucla.edu. ^[1] UCLA Medical Center, Internal Medicine, Los Angeles CA. ^[2] UCLA Medical Center, Hematology Oncology, Los Angeles CA. ^[3]

关键词 B-cell lymphoma Chimeric antigen receptor T-cell therapy Double-hit lymphoma Lymphoma Non-hodgkin lymphoma

主题词生物制品(Biological Products);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);肿瘤复发, 局部(Neoplasm Recurrence, Local);受体, 抗原, T细胞(Receptors, Antigen, T-Cell);回顾性研究(Retrospective Studies)

DOI 10.1016/j.clml.2021.07.002

PMID 34389271

发布时间 2022-04-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交